eTheRNA-led international consortium starts preclinical studies of cross-strain protective COVID-19 mRNA vaccine for high risk populations
16 July 2020
March 19, 2020 Niel, Belgium, (‘eTheRNA’ or The Company’), a clinical-stage company developing vaccines from its proprietary mRNA TriMix platform, today announced that the consortium it leads with Chinese, North American and European partne...
REPROCELL announce the launch of StemRNA™ Entero human iPSC-derived intestinal epithelial cells
15 July 2020
Yokahoma, Japan: REPROCELL announce the launch of StemRNA™ Entero: human iPSC-derived intestinal epithelial cells. StemRNA™ Entero cells are intestinal epithelial cells derived from human iPSCs. This model was developed using advanced techn...
REPROCELL’s Personal iPS Service is Launched in Japan
15 July 2020
Yokohama, Japan: REPROCELL is delighted to announce the launch a new service for consumers, Personal iPS, in which induced pluripotent stem cells (iPSCs) re established for future regenerative medicine treatment. Create a new (potential) me...
Why eTheRNA's mRNA vaccine may offer a long-term solution to COVID
13 July 2020
REPROCELL has recently joined an international consortium, led by Belgium company etheRNA, to develop a novel mRNA vaccine against CoV-2. Administered intranasally, the proposed vaccine is intended primarily for high risk populations such a...
Phase II clinical trial of regenerative medicine product Stemchymal® - Recruitment of first patient
28 February 2020
REPROCELL is pleased to announce that the first patient has been registered and the test article administered at Nagoya University in the Phase II clinical trial of the regenerative medicine product Stemchymal®. Stemchymal® aims to tackle a...
Prof Stefan Przyborski to give Keynote Address at this year’s SMi 3D Cell Culture Conference
13 February 2020
Dates: 19-20 February 2020 Venue: Copthorne Tara, London, United Kingdom Website: https://www.smi-online.co.uk/pharmaceuticals/uk/3D-Cell-Culture REPROCELL Europe’s CSO Professor Stefan Przyborski will giving the keynote address on 3D cell ...
Patients with IBD absorb drugs differently from healthy individuals
16 January 2020
A recent study by researchers from REPROCELL found that IBD patients display different drug absorption profiles to healthy individuals. This is the first time that drug absorption has been estimated using inflamed GI tissue from this patien...
REPROCELL can now predict oral bioavailability in fresh IBD tissue
14 January 2020
Glasgow, UK: REPROCELL (Biopta) today announced that they can predict test article permeability using gastrointestinal (GI) resections from Inflammatory Bowel Disease (IBD) donors. This service, which is first of its kind to market, will al...
Early understanding of pharmacology and genomics can improve precision medicine strategies
23 December 2019
Glasgow, UK: REPROCELL (Biopta) today announced the successful publication of a novel study in pharmacology and genomics to improve strategies for the development of precision medicines. The study – performed in collaboration with the NHS, ...
Lantern Pharma Selects REPROCELL Inc., for Drug Screening and Biomarker Discovery Services
13 November 2019
Lantern Pharma a clinical stage oncology biotech leveraging A.I. and machine learning genomics company has selected REPROCELL Inc. to provide drug screening and drug sensitivity services. BELTSVILLE, MD. (PRWEB) NOVEMBER 12, 2019: REPROCELL...